Literature DB >> 19641002

Dominant CD8+ T-lymphocyte responses suppress expansion of vaccine-elicited subdominant T lymphocytes in rhesus monkeys challenged with pathogenic simian-human immunodeficiency virus.

Edwin R Manuel1, Wendy W Yeh, Michael S Seaman, Kathryn Furr, Michelle A Lifton, Sandrine L Hulot, Patrick Autissier, Norman L Letvin.   

Abstract

Emerging data suggest that a cytotoxic T-lymphocyte response against a diversity of epitopes confers greater protection against a human immunodeficiency virus/simian immunodeficiency virus infection than does a more focused response. To facilitate the creation of vaccine strategies that will generate cellular immune responses with the greatest breadth, it will be important to understand the mechanisms employed by the immune response to regulate the relative magnitudes of dominant and nondominant epitope-specific cellular immune responses. In this study, we generated dominant Gag p11C- and subdominant Env p41A-specific CD8(+) T-lymphocyte responses in Mamu-A*01(+) rhesus monkeys through vaccination with plasmid DNA and recombinant adenovirus encoding simian-human immunodeficiency virus (SHIV) proteins. Infection of vaccinated Mamu-A*01(+) rhesus monkeys with a SHIV Gag Deltap11C mutant virus generated a significantly increased expansion of the Env p41A-specific CD8(+) T-lymphocyte response in the absence of secondary Gag p11C-specific CD8(+) T-lymphocyte responses. These results indicate that the presence of the Gag p11C-specific CD8(+) T-lymphocyte response following virus challenge may exert suppressive effects on primed Env p41A-specific CD8(+) T-lymphocyte responses. These findings suggest that immunodomination exerted by dominant responses during SHIV infection may diminish the breadth of recall responses primed during vaccination.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19641002      PMCID: PMC2748023          DOI: 10.1128/JVI.01015-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  52 in total

1.  A previously unrecognized H-2D(b)-restricted peptide prominent in the primary influenza A virus-specific CD8(+) T-cell response is much less apparent following secondary challenge.

Authors:  G T Belz; W Xie; J D Altman; P C Doherty
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

2.  Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses.

Authors:  W Chen; L C Antón; J R Bennink; J W Yewdell
Journal:  Immunity       Date:  2000-01       Impact factor: 31.745

Review 3.  Immunodominance and immunodomination: critical factors in developing effective CD8+ T-cell-based cancer vaccines.

Authors:  Weisan Chen; James McCluskey
Journal:  Adv Cancer Res       Date:  2006       Impact factor: 6.242

4.  Contribution of T-cell receptor repertoire breadth to the dominance of epitope-specific CD8+ T-lymphocyte responses.

Authors:  Edwin R Manuel; William A Charini; Pritha Sen; Fred W Peyerl; Marcelo J Kuroda; Jörn E Schmitz; Patrick Autissier; Dennis A Sheeter; Bruce E Torbett; Norman L Letvin
Journal:  J Virol       Date:  2006-10-11       Impact factor: 5.103

5.  Immunodomination in the evolution of dominant epitope-specific CD8+ T lymphocyte responses in simian immunodeficiency virus-infected rhesus monkeys.

Authors:  Michael H Newberg; Kimberly J McEvers; Darci A Gorgone; Michelle A Lifton; Susanne H C Baumeister; Ronald S Veazey; Jörn E Schmitz; Norman L Letvin
Journal:  J Immunol       Date:  2006-01-01       Impact factor: 5.422

6.  Mamu-I: a novel primate MHC class I B-related locus with unusually low variability.

Authors:  J A Urvater; N Otting; J H Loehrke; R Rudersdorf; I I Slukvin; M S Piekarczyk; T G Golos; A L Hughes; R E Bontrop; D I Watkins
Journal:  J Immunol       Date:  2000-02-01       Impact factor: 5.422

7.  Attrition of T cell memory: selective loss of LCMV epitope-specific memory CD8 T cells following infections with heterologous viruses.

Authors:  L K Selin; M Y Lin; K A Kraemer; D M Pardoll; J P Schneck; S M Varga; P A Santolucito; A K Pinto; R M Welsh
Journal:  Immunity       Date:  1999-12       Impact factor: 31.745

8.  Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia.

Authors:  T M Allen; D H O'Connor; P Jing; J L Dzuris; B R Mothé; T U Vogel; E Dunphy; M E Liebl; C Emerson; N Wilson; K J Kunstman; X Wang; D B Allison; A L Hughes; R C Desrosiers; J D Altman; S M Wolinsky; A Sette; D I Watkins
Journal:  Nature       Date:  2000-09-21       Impact factor: 49.962

9.  Clonal focusing of epitope-specific CD8+ T lymphocytes in rhesus monkeys following vaccination and simian-human immunodeficiency virus challenge.

Authors:  Pritha Sen; William A Charini; Ramu A Subbramanian; Edwin R Manuel; Marcelo J Kuroda; Patrick A Autissier; Norman L Letvin
Journal:  J Virol       Date:  2007-10-31       Impact factor: 5.103

10.  T cells compete for access to antigen-bearing antigen-presenting cells.

Authors:  R M Kedl; W A Rees; D A Hildeman; B Schaefer; T Mitchell; J Kappler; P Marrack
Journal:  J Exp Med       Date:  2000-10-16       Impact factor: 14.307

View more
  8 in total

1.  Post-translational intracellular trafficking determines the type of immune response elicited by DNA vaccines expressing Gag antigen of Human Immunodeficiency Virus Type 1 (HIV-1).

Authors:  Aaron Wallace; Kim West; Alan L Rothman; Francis A Ennis; Shan Lu; Shixia Wang
Journal:  Hum Vaccin Immunother       Date:  2013-08-13       Impact factor: 3.452

2.  In silico design of a DNA-based HIV-1 multi-epitope vaccine for Chinese populations.

Authors:  Yi Yang; Weilai Sun; Jingjing Guo; Guangyu Zhao; Shihui Sun; Hong Yu; Yan Guo; Jungfeng Li; Xia Jin; Lanying Du; Shibo Jiang; Zhihua Kou; Yusen Zhou
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Vaccination reduces simian-human immunodeficiency virus sequence reversion through enhanced viral control.

Authors:  Edwin R Manuel; Wendy W Yeh; Harikrishnan Balachandran; Ryon H Clarke; Michelle A Lifton; Norman L Letvin
Journal:  J Virol       Date:  2010-09-29       Impact factor: 5.103

4.  Antigenic requirement for Gag in a vaccine that protects against high-dose mucosal challenge with simian immunodeficiency virus.

Authors:  John B Schell; Kapil Bahl; Ewa Folta-Stogniew; Nina Rose; Linda Buonocore; Preston A Marx; Ratish Gambhira; John K Rose
Journal:  Virology       Date:  2015-01-12       Impact factor: 3.616

Review 5.  Reverse vaccinology: developing vaccines in the era of genomics.

Authors:  Alessandro Sette; Rino Rappuoli
Journal:  Immunity       Date:  2010-10-29       Impact factor: 31.745

6.  Infection with "escaped" virus variants impairs control of simian immunodeficiency virus SIVmac239 replication in Mamu-B*08-positive macaques.

Authors:  Laura E Valentine; John T Loffredo; Alex T Bean; Enrique J León; Caitlin E MacNair; Dominic R Beal; Shari M Piaskowski; Yann C Klimentidis; Simon M Lank; Roger W Wiseman; Jason T Weinfurter; Gemma E May; Eva G Rakasz; Nancy A Wilson; Thomas C Friedrich; David H O'Connor; David B Allison; David I Watkins
Journal:  J Virol       Date:  2009-09-02       Impact factor: 5.103

7.  The Immunodominance Change and Protection of CD4+ T-Cell Responses Elicited by an Envelope Protein Domain III-Based Tetravalent Dengue Vaccine in Mice.

Authors:  Hsin-Wei Chen; Hui-Mei Hu; Szu-Hsien Wu; Chen-Yi Chiang; Yu-Ju Hsiao; Chia-Kai Wu; Chun-Hsiang Hsieh; Han-Hsuan Chung; Pele Chong; Chih-Hsiang Leng; Chien-Hsiung Pan
Journal:  PLoS One       Date:  2015-12-29       Impact factor: 3.240

8.  Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP.

Authors:  Carly M Bliss; Georgina Bowyer; Nicholas A Anagnostou; Tom Havelock; Claudia M Snudden; Huw Davies; Simone C de Cassan; Amy Grobbelaar; Alison M Lawrie; Navin Venkatraman; Ian D Poulton; Rachel Roberts; Pooja B Mange; Prateek Choudhary; Saul N Faust; Stefano Colloca; Sarah C Gilbert; Alfredo Nicosia; Adrian V S Hill; Katie J Ewer
Journal:  Sci Rep       Date:  2018-02-21       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.